Why CVS Is Giving Plans A New Tool To Target High Launch Prices
Dr. Robert Dubois of the National Pharmaceutical Council (NPC) has expressed his concerns about CVS Health’s new service offering that allows
Read moreArchived News
Trump administration moves to give Medicare drug plans more control over their offerings
The Trump administration moved Wednesday to give Medicare drug plans more choices in the products they can offer patients, in
Read moreWill CMS Pop the Gross-to-Net Bubble in Medicare Part D With Point-of-Sale Rebates?
Last week, the Centers for Medicare & Medicaid Services (CMS) released its 713-page proposed policy changes and updates for the
Read moreLewis Carroll and the Pricing of Pharmaceuticals
Imagine a pharmaceutical market designed by Lewis Carroll’s Mad Hatter. In contrast to almost every other market, he might begin
Read morePharmacists Should Have Plans in Place for Disasters
Disasters like major storms, earthquakes, wildfires, and terrorist actions happen. Pharmacists should have plans in place that allow them to
Read moreCOA Representatives Join Congressional Briefing on Personalized Medicine and the Future of Cancer Care Delivery and Payment
Representatives from the Community Oncology Alliance (COA) joined other cancer stakeholders and policymakers on Capitol Hill today for a briefing
Read moreIt’s time to reform accessibility to prescription drugs
Too many Americans can’t readily access or afford their prescription drugs. Pharmacy benefit managers (PBMs) play a central role in
Read moreCancer drugs’ high prices not justified by cost of development, study contends
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D)
Read moreCancer immunotherapy proves itself in earlier-stage disease
MADRID (Reuters) – Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the
Read moreClovis CEO deems new Rubraca data ‘better’ than its PARP rivals. Is it enough?
Clovis Oncology may be the middle child in the new wave of ovarian cancer treatments, but it’s hoping some new
Read more